Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS) is a healthcare company (biotechnology) based in the United States. The share price is $297.37, down 0.18% on the day, which values the company at $8.81B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $297.37−0.18% today
- Market value
- $8.81B
- P/E ratio
- 40.4×last 12 months
- Forward P/E
- 32.2×
- Funk Score
- 73/100
- Against its own history
- Above its usual priceusual price $246.54
- 200-week average
- $185.5760% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Krystal Biotech, Inc. in more detail
KRYS trades at 40.4× its last twelve months' earnings, 32.2× next year's expected earnings, 18.7× sales. Measured against its own history, the price is 21% above what its usual multiples would imply ($246.54) — above its usual price. It sits 60% above its 200-week average of $185.57.
Its Funk Score is 73 out of 100 (financial strength 9.2, profitability 8.6, value 4.2, each out of 10).
In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.
Health Care companies of similar size
- Globus MedicalGMED
- Madrigal PharmaceuticalsMDGL
- Henry ScheinHSIC
- Oscar HealthOSCR
- TG TherapeuticsTGTX
- Praxis Precision MedicinesPRAX
- Twist BioscienceTWST
- Protagonist TherapeuticsPTGX
- 10x GenomicsTXG
- HealthEquityHQY
- Corcept TherapeuticsCORT
- Rhythm PharmaceuticalsRYTM
Side by side:KRYS vs PTGX (Krystal Biotech, Inc. vs Protagonist Therapeutics)KRYS vs TWST (Krystal Biotech, Inc. vs Twist Bioscience)KRYS vs PRAX (Krystal Biotech, Inc. vs Praxis Precision Medicines)KRYS vs TXG (Krystal Biotech, Inc. vs 10x Genomics)KRYS vs HQY (Krystal Biotech, Inc. vs HealthEquity)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Krystal Biotech, Inc. (KRYS): questions and answers
What is KRYS's P/E ratio?
Krystal Biotech, Inc. trades at 40.4× its last twelve months' earnings and 32.2× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 36.0× to 318.1×, with a median of 52.2×.
What is Krystal Biotech, Inc.'s market cap?
Krystal Biotech, Inc. is valued at $8.81B at a share price of $297.37.
Is KRYS overvalued or undervalued?
Against its own history, KRYS is above its usual price: the price is 21% above the $246.54 implied by the median multiples it has traded at (price / earnings, price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is KRYS above its 200-week moving average?
Yes. KRYS is 60.2% above its 200-week average of $185.57. Long-term investors watch that line because strong companies rarely trade below it for long.
Does KRYS pay a dividend?
Krystal Biotech, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Krystal Biotech, Inc. (KRYS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/KRYS
Underlying data: Yahoo Finance; company filings with the SEC.